| P2093 | author name string | Yan Zhou | |
| | Chun-Bin Wang | |
| | Yun-Long Tang | |
| | Yong-Zhong Su | |
| | Ling-Ling Cheng | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray | Q28204313 |
| | Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab | Q28256567 |
| | The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP | Q28274089 |
| | Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. | Q30395557 |
| | Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms | Q33857031 |
| | BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo | Q35066871 |
| | Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis | Q35111804 |
| | Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis | Q35723777 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone | Q36267666 |
| | Rituximab therapy in malignant lymphoma | Q36832102 |
| | MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr | Q37006876 |
| | Lymphoma classification: the quiet after the storm | Q37917733 |
| | Diffuse large B cell lymphoma: how can we cure more patients in 2012? | Q37992727 |
| | Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. | Q38827910 |
| | BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma | Q40357519 |
| | Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). | Q44308339 |
| | A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer | Q44372847 |
| | Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? | Q44408913 |
| | Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study | Q44845444 |
| | BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab | Q46068969 |
| | Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. | Q50495776 |
| | Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. | Q53456604 |
| | High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy. | Q53662425 |
| | Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial G | Q56784798 |
| | CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma | Q80497243 |
| | High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy | Q83633345 |
| | Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? | Q85501483 |
| P433 | issue | 3 | |
| P304 | page(s) | 3767-3773 | |
| P577 | publication date | 2017-07-15 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma | |
| P478 | volume | 14 | |